latest news releases from the newsroom
MorphoSys Inaugurates New Facilities in Oxford, U.K.: U.K. Minister of Science Malcolm Wicks Presides Over Opening Ceremonies
MARTINSRIED, Germany, Jan. 22, 2007 (PRIME NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX), a leading German-based biotechnology company, announced today that it has opened new U.K. headquarters in Kidlington, North Oxford. The 2,200 square meter facility acts as the new U.K. headquarters for the MorphoSys Group of companies situated in the U.K. Today's official opening ceremony was performed by U.K. Minister of State for Science and Innovation, Malcolm Wicks. Dr. Simon Moroney, Chief Executive Officer of MorphoSys Group, also attended along with Chief Financial Officer Dave Lemus, Head of AbD Serotec Dieter Lingelbach, Tim Bernard, Head of Sales of AbD Serotec and the Managing Director of AbD Serotec James Bernard.
Dow Jones Financial Information Services
U.S. Venture Capital Investing in 2006 Posts a Five-Year High, Reaching $25.75 Billion, Highest Annual Investment Level Since 2001
SAN FRANCISCO and NEW YORK, Jan. 22, 2007 (PRIME NEWSWIRE) -- Venture capital investment into U.S. headquartered companies continued its ascent in 2006 with the most annual deal flow and capital investment since 2001, according to the Quarterly Venture Capital Report released by Ernst & Young LLP and Dow Jones VentureOne, the publisher of the VentureSource database. In total, deal count reached 2,454 deals for the year, slightly ahead of 2005's level, and capital investment reached $25.75 billion, an 8% increase over the preceding year.